Show simple item record

dc.contributor.authorCollins, JJen_US
dc.contributor.authorDevine, TDen_US
dc.contributor.authorDick, GSen_US
dc.contributor.authorJohnson, EAen_US
dc.contributor.authorKilham, HAen_US
dc.contributor.authorPinkerton, CRen_US
dc.contributor.authorStevens, MMen_US
dc.contributor.authorThaler, HTen_US
dc.contributor.authorPortenoy, RKen_US
dc.date.accessioned2018-09-18T14:40:30Z
dc.date.issued2002-01en_US
dc.identifier1en_US
dc.identifier.citationJOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2002, 23 pp. 10 - 16en_US
dc.identifier.issn0885-3924en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2791
dc.identifier.doi10.1016/S0885-3924(01)00375-Xen_US
dc.description.abstractFew studies have attempted to describe the experience of symptoms in young children with cancer. This is due, in part, to the lack of validated symptom assessment scales for this patient population. The objective of this study was to evaluate the reliability and validity of a revised Memorial Symptom Assessment Scale (MSAS) in patients aged 7-12 as an instrument for the assessment of symptoms in young children with cancer. The MSAS (7-12) was administered to 149 children (inpatients and outpatients) who were undergoing treatment at either the Royal Marsden NHS Trust, London, United Kingdom or The Children’s Hospital at Westmead, Sydney Australia. Validity was evaluated by comparison with the medical record, parental report, and concurrent assessment on visual analogue scales for selected symptoms. The data provide evidence of the reliability and validity of MSAS (7-12) and demonstrate that children with cancer as young as 7 years can report clinically relevant and consistent information about their symptom experience. Young children with cancer experience multiple symptoms. Approximately one-third had experienced lethargy and/or pain and/or insomnia during the 48 hours prior to the completion of MSAS (7-12). The completion rate of MSAS (7-12) was high and the majority of children completed the instrument in a short period of time and with little difficulty. The instrument appears to be age appropriate and may be helpful to older children unable to independently complete MSAS (10-18). Systematic symptom assessment may be useful in future epidemiological studies of symptoms and in cancer chemotherapy drug trial. J Pain Symptom Manage 2002:23:10-16 (C) Cancer Pain Relief Committee, 2002.en_US
dc.format.extent10 - 16en_US
dc.titleThe measurement of symptoms in young children with cancer: The validation of the Memorial Symptom Assessment Scale in children aged 7-12en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/S0885-3924(01)00375-Xen_US
rioxxterms.licenseref.startdate2002-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJOURNAL OF PAIN AND SYMPTOM MANAGEMENTen_US
pubs.notesresearcherid-numbers: pinkerton, ross/I-4808-2014 unique-id: ISI:000173317800006en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.volume23en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorPinkerton, Rossen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record